Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Dare Bioscience, Inc. (DARE)
Last dare bioscience, inc. earnings: 8/14 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.darebioscience.com/investor-relations
Company Research
Source: GlobeNewswire
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trialInitiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré. “In 2019, our goal is to continue delivering on meaningful milestones, including: the conclusion and read-out of our pre-pivotal enabling clinical study of our non-hormonal contraceptive Ovaprene; the initiation of a pivotal Phase 3 study for DARE-BV1 for bacterial vaginosis; the initiation of the at-home portion of
Show less
Read more
Impact Snapshot
Event Time:
DARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DARE alerts
High impacting Dare Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
DARE
News
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1GlobeNewswire
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveGlobeNewswire
- Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateGlobeNewswire
DARE
Earnings
- 8/10/23 - Miss
DARE
Sec Filings
- 4/16/24 - Form PRE
- 3/29/24 - Form S-3
- 3/29/24 - Form S-3
- DARE's page on the SEC website